Anecortave (rINN) is a novel angiogenesis inhibitor used in the treatment of the exudative (wet) form of age-related macular degeneration. Although based on a steroid nucleus, which can be derived from cortisol, it possesses little glucocorticoid activity. It will be marketed by Alcon as anecortave acetate for depot suspension under the trade name Retaane.

CAS：7753-60-8
中文别名：乙酸阿奈可他;
英文别名：2-((10S,13S,17R)-17-hydroxy-10,13-dimethyl-3-oxo-2,3,6,7,8,10,12,13,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-17-yl)-2-oxoethyl acetate;21-Acetoxy-17-hydroxy-pregna-4,9(11)-dien-3,20-dion;Retaane;21-acetoxy-17-hydroxy-pregna-4,9(11)-diene-3,20-dione;AL-3789;2-((8S,10S,13S,14S,17R)-17-hydroxy-10,13-dimethyl-3-oxo-2,3,6,7,8,10,12,13,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-17-yl)-2-oxoethyl acetate;Anecortave acetate;Anecortave;Retaane suspension;
分子式：C23H30O5
分子量：386.481
精确质量：386.209
Psa：80.67
Logp：3.3017

UNII：Y0PC411K4T

密度：1.23g/cm3
沸点：551.8ºC at 760 mmHg
闪点：188.4ºC
折射率：1.572

用途
确炎舒松A醋酸酯、肤轻松醋酸酯、氟氢可的松醋酸酯的中间体。